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5-Year Clinical Outcomes
in the ICTUS (Invasive versus Conservative
Treatment in Unstable coronary Syndromes) Trial
A Randomized Comparison of an Early
Invasive Versus Selective Invasive Management in Patients
With Non–ST-Segment Elevation Acute Coronary Syndrome
Peter Damman, MD, Alexander Hirsch, MD, Fons Windhausen, MD, Jan G. P. Tijssen, PHD,
Robbert J. de Winter, MD, PHD, for the ICTUS Investigators
Amsterdam, the Netherlands
Objectives We present the 5-year clinical outcomes according to treatment strategy with additional risk stratification of the
ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial.
Background Long-term outcomes may be relevant to decide treatment strategy for patients presenting with non–ST-segment
elevation acute coronary syndromes (NSTE-ACS) and elevated troponin T.
Methods We randomly assigned 1,200 patients to an early invasive or selective invasive strategy. The outcomes were the
composite of death or myocardial infarction (MI) and its individual components. Risk stratification was per-
formed with the FRISC (Fast Revascularization in InStability in Coronary artery disease) risk score.
Results At 5-year follow-up, revascularization rates were 81% in the early invasive and 60% in the selective invasive
group. Cumulative death or MI rates were 22.3% and 18.1%, respectively (hazard ratio [HR]: 1.29, 95% confi-
dence interval [CI]: 1.00 to 1.66, p  0.053). No difference was observed in mortality (HR: 1.13, 95% CI: 0.80 to
1.60, p  0.49) or MI (HR: 1.24, 95% CI: 0.90 to 1.70, p  0.20). After risk stratification, no benefit of an early
invasive strategy was observed in reducing death or spontaneous MI in any of the risk groups.
Conclusions In patients presenting with NSTE-ACS and elevated troponin T, we could not demonstrate a long-term benefit of
an early invasive strategy in reducing death or MI. (Invasive versus Conservative Treatment in Unstable coronary
Syndromes [ICTUS]; ISRCTN82153174) (J Am Coll Cardiol 2010;55:858–64) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.026T
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the American College of Cardiology (ACC)/American
eart Association (AHA) and European Society of Cardi-
logy guidelines recommend an early invasive strategy for
atients presenting with non–ST-segment elevation acute
oronary syndrome (NSTE-ACS) without life-threatening
ymptoms but with high-risk features (1,2). An early inva-
ive strategy consists of coronary angiography within 24 to
2 h, with subsequent revascularization when indicated.
rom the Department of Cardiology, Academic Medical Center–University of
msterdam, Amsterdam, the Netherlands. The ICTUS study was supported by the
nteruniversitary Cardiology Institute of the Netherlands (ICIN), the Working
roup on Cardiovascular Research of the Netherlands (WCN), and educational
rants from Eli Lilly, Sanofi/Synthelabo, Sanofi-Aventis, Pfizer, and Medtronic.
oche Diagnostics, the Netherlands, kindly provided the reagents for Core Labora-
ory cardiac troponin T measurements.s
Manuscript received August 3, 2009; revised manuscript received November 5,
009, accepted November 20, 2009.his recommendation is supported by meta-analyses show-
ng evidence of an early hazard balanced by a late benefit,
esulting in a significant reduction in death or myocardial
nfarction (MI) (3–5).
See page 865
The ICTUS (Invasive versus Conservative Treatment in
nstable coronary Syndromes) trial compared an early
nvasive with a selective invasive strategy in patients with
STE-ACS and positive troponin T (6). The ICTUS trial
howed no benefit of the early invasive strategy for the
omposite of death, MI, or rehospitalization for anginal
ymptoms at 1- and 3-year follow-up (6,7). For patients
tabilized on medical treatment, a Class IIb recommenda-
ion was included in the ACC/AHA guidelines for a
elective invasive strategy (1).
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March 2, 2010:858–64 5-Year Clinical Outcomes in the ICTUS TrialThe 5-year results of the RITA-3 (Randomized Interven-
ion Trial of unstable Angina 3) and FRISC II (Fast Revas-
ularization in InStability in Coronary artery disease II) trials
oth emphasized the importance of long-term outcomes,
howing differences in short-term and long-term mortality
8,9). Moreover, these studies showed a beneficial effect of the
nvasive strategy, most apparent in high-risk patients. To
nvestigate the occurrence of late clinical events, we present the
-year clinical outcomes of death and MI of the ICTUS trial,
ith additional subgroup analyses by categories of baseline risk.
ethods
tudy design. The design of the Dutch multicenter ICTUS
rial has been published previously (6). In short, 1,200 patients
ith NSTE-ACS and elevated cardiac troponin T were
andomized to an early invasive or a selective invasive strategy.
atients. Patients (age 18 to 80 years) were eligible if the
ollowing criteria were met: symptoms of ischemia that were
ncreasing or occurring at rest, with the last episode occur-
ing 24 h before randomization; elevated cardiac troponin
level (0.03 g/l); and either ischemic changes as
ssessed by electrocardiography or a documented history of
oronary artery disease. Exclusion criteria were: ST-
egment elevation MI 48 h; an indication for reperfusion
herapy; hemodynamic instability or overt congestive heart
ailure; and an increased risk of bleeding. The collection of
ong-term follow-up was planned in the protocol andFigure 1 Trial Profilepproved by the authorized eth-
cs committee. All patients pro-
ided written informed consent.
andomization and study
rotocol. In the early invasive
trategy, patients were scheduled
o undergo coronary angiography
ithin 24 to 48 h and revascular-
zation when appropriate. Patients
n the selective invasive strategy
ere medically stabilized, with an-
iography and revascularization in
ase of refractory angina, hemody-
amic or rhythmic instability, or clinically significant ischemia
n the pre-discharge exercise test. Pharmacological treatment
onsisted of aspirin, clopidogrel, enoxaparin, or abciximab
uring all percutaneous coronary interventions (PCI), and
ntensive lipid-lowering therapy (6).
ollow-up. Patients were contacted by telephone after 5
ears from randomization. All potential outcome events
ere recorded; hospitalizations were reviewed for potential
utcome events unless there was an unequivocally noncar-
iac reason for admission. If a patient could not be con-
acted, information was obtained from the patient’s family,
eneral practitioner, treating cardiologist, and hospital
ecords. Follow-up was censored at the date of last tele-
hone contact, or at 5 years, whichever came first. If the
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
HR  hazard ratio
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation
acute coronary syndrome
PCI  percutaneous
coronary intervention
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5-Year Clinical Outcomes in the ICTUS Trial March 2, 2010:858–64atient was lost to follow-up, censoring was done at the date
f last clinical follow-up. Information on vital status was
btained from the Dutch national population registry and
as verified until September 12, 2008. Cause of death was
btained from the general practitioner and hospital records.
ollow-up for mortality was censored at 5 years. If a patient
ould not be identified in the national registry, censoring
as done at the date of last clinical follow-up.
utcomes. The main outcomes were the composite of
eath or recurrent MI, composite of death or spontaneous
I, and the individual components death, cardiovascular
eath, MI, first spontaneous MI, and first procedure-related
I. Cardiovascular death was defined as all-cause death,
nless an unequivocal noncardiovascular cause could be
stablished. Myocardial infarction was defined as docu-
ented myocardial necrosis either in the setting of myocar-
ial ischemia (spontaneous MI) or in the setting of PCI or
oronary artery bypass grafting (CABG) (procedure-related
I) following the recommendations of the Consensus
ommittee for the definition of MI (10). All new events
ccurring after previous reported data were adjudicated
linded to treatment allocation (R.J.d.W. and P.D.) (7).
tatistical analysis. Analysis was by intention-to-treat.
umulative event rates were estimated using the Kaplan-
eier method. Hazard ratios (HRs) with 95% confidence
Baseline CharacteristicsTable 1 Baseline Characteristics
Ea
Demographics
Age 65 yrs, n (%)
Body mass index, kg/m2, mean  SD
Male sex, n (%)
Clinical history, n (%)
Myocardial infarction
Percutaneous coronary intervention
Coronary artery bypass grafting
Risk factors, n (%)
Current cigarette smoking
Hypertension
Hypercholesterolemia
Diabetes
Family history of coronary artery disease
Electrocardiographic abnormalities, n (%)
ST-segment deviation 0.1 mV
Left bundle branch block
Aspirin use at admission, n (%)
Laboratory assessments, median (IQR)
Troponin T, g/l
C-reactive protein, mg/l
Creatinine clearance, ml/min/1.73 m2
FRISC score, n (%)
Low risk, score 1–2
Intermediate risk, score 3–4
High risk, score 5–7C-reactive protein measurements were available in 1,144 patients. Electroca
FRISC  Fast Revascularization in InStability in Coronary artery disease; IQntervals (CIs) were obtained with Cox proportional hazards
odels, including treatment strategy as the only covariate.
Pre-specified subgroup analyses included gender, and
aseline risk according to the FRISC score. All patients
ere stratified by the FRISC score, being the sum of the
ollowing 7 factors present at admission: age 65 years,
ale sex, history of MI, diabetes mellitus, ST-segment
epression, elevated troponin T concentration (0.03 g/l),
nd elevated C-reactive protein concentration (10 mg/l)
7,11). ST-segment depression was considered present in
ase of left bundle branch block (12). Statistical analyses
ere done with the Statistical Package for Social Sciences
SPSS version 15.0 for Windows, Chicago, Illinois).
esults
atients. A total of 604 patients were assigned to the early
nvasive and 596 patients to the selective invasive strategy
Fig. 1). Baseline characteristics were well balanced among
he 2 groups (Table 1). The median duration of initial
ospitalization was 6 days in the early invasive and 7 days in
he selective invasive strategy, during which 76% and 40% of
atients, respectively, had been revascularized. Five-year
umulative revascularization was 81% in the early invasive
nd 60% in the selective invasive strategy; CABG was the
asive Strategy
 604)
Selective Invasive Strategy
(n  596)
(44) 266 (45)
 4 27 4
(74) 434 (73)
(25) 125 (21)
(13) 63 (11)
(10) 43 (7)
(40) 248 (42)
(37) 240 (40)
(35) 206 (35)
(14) 80 (13)
(44) 241 (40)
(49) 290 (51)
(1) 6 (1)
(39) 221 (37)
(0.12–0.78) 0.29 (0.13–0.69)
(1.7–9.6) 4.3 (1.9–11.4)
(68–103) 85 (70–103)
(27) 173 (29)
(61) 346 (58)
(12) 77 (13)rly Inv
(n
263
27
446
153
77
62
244
226
211
86
263
284
8
235
0.29
3.5
85
163
368
73rdiography data were available in 1,149 patients.
R  interquartile range.
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March 2, 2010:858–64 5-Year Clinical Outcomes in the ICTUS Trialrst procedure in 23% and 25%, respectively. Figure 2 shows
evascularization over time.
utcomes. At 5-year follow-up, information on vital status
as available for 1,193 patients (99.4%) and information on
I for 1,176 patients (98.0%). Five-year outcomes are shown
n Table 2. A higher death or MI hazard was observed in the
arly invasive group (22.3% in the early invasive and 18.1% in
he selective invasive group; HR: 1.29, 95% CI: 1.00 to 1.66,
 0.053). No difference was observed in the composite of
eath or spontaneous MI (17.5% in the early invasive and
6.1% in the selective invasive group; HR: 1.10, 95% CI: 0.83
o 1.45, p  0.52). Five-year mortality was 11.1% and 9.9%,
espectively (HR: 1.13, 95% CI: 0.80 to 1.60, p  0.49). No
ifference was observed in cardiovascular death (HR: 0.95,
5% CI: 0.61 to 1.47, p  0.80). A slight trend towards an
ncreased noncardiovascular mortality was observed in the early
nvasive group (HR: 1.52, 95% CI: 0.85 to 2.71, p 0.16). MI
ates were 13.9% and 11.7%, respectively (HR: 1.24, 95% CI:
.90 to 1.70, p  0.20). No sex-associated differences were
bserved in the composite of death or spontaneous MI (male:
Figure 2 Revascularization Procedures Over Time
The Kaplan-Meier estimates for revascularization at 5 years were 81% in the early
invasive group compared with 60% in the selective invasive group. CABG  coro-
nary artery bypass grafting; EI  early invasive strategy; PCI  percutaneous coro-
nary intervention; SI  selective invasive strategy.
Cumulative Event Rate and Hazard Ratios of theo posite Outcome and the Individu l OutcomTable 2 Cumulative Event Rate and HazardComposite Outcome and the Individ
Early Invasive
(n  604)†
Sel
Death or MI‡ 134 (22.3)
Death or spontaneous MI 105 (17.5)
All-cause death 67 (11.1)
Cardiovascular death 38 (6.5)
MI 82 (13.9)
Spontaneous MI 50 (8.6)
Procedure-related MI 38 (6.4)
Values are n (%). *p value derived from Cox proportional hazards mod
the recommendations of the Consensus Committee for the Universal Definiti
CI  confidence interval.R: 1.22, 95% CI: 0.87 to 1.71, p  0.24; female: HR: 0.87,
5% CI: 0.53 to 1.43, p  0.59). Kaplan-Meier curves are
hown in Figures 3 and 4.
Patients who endured a major bleeding during initial
ospitalization were at a higher risk for 5-year mortality
ompared with those who did not (17.2% vs. 10.4%, HR:
.81, 95% CI: 0.74 to 4.43, p  0.19).
isk stratification. After stratification by the FRISC
core, higher death or spontaneous MI rates were observed
ith increasing risk scores; 9.9% in the low-risk (scores 1 to
), 16.8% in the intermediate-risk (scores 3 to 4), and 32.1%
n the high-risk group (scores 5 to 7). No significant benefit
rom an early invasive treatment was observed in any of the
isk groups; low-risk HR: 1.13 (95% CI: 0.57 to 2.24, p 
.72), intermediate-risk HR: 1.06 (95% CI: 0.74 to 1.52,
 0.74), and high-risk HR: 1.15 (95% CI: 0.66 to 2.03,
 0.62) (Fig. 5A). For illustrative purposes, Figure 5B
hows Kaplan-Meier curves after stratification using cutoff
cores as defined in the long-term results of the FRISC II
rial (9). The low-risk group (scores 0 to 1) is not shown,
ncluding only 3.7% of all patients. The intermediate-risk
roup includes 57.5% and the high-risk group 38.8% of all
atients. Again, no benefit was observed with an early
nvasive strategy: low-risk HR: 0.52 (95% CI: 0.09 to 2.81,
 0.44), intermediate-risk HR: 0.90 (95% CI: 0.57 to
.42, p  0.66), and high-risk HR: 1.27 (95% CI: 0.89 to
.82, p  0.20).
iscussion
he present analysis confirms and extends our previous
eports, as we could not demonstrate that in patients
resenting with NSTE-ACS and an elevated troponin T,
n early invasive strategy was superior to a selective invasive
trategy in reducing 5-year death or MI. In addition, there
ere no differences in the individual components of the
omposite outcome. No late effects were observed, with
omparable increments in the outcomes death and MI in
oth treatment groups up to 5-year follow-up.
A slight trend towards an increase in noncardiovascular
ortality was observed in the early invasive group, but this
ifference did not reach statistical significance (p 0.16). In
5 Yearss of the
utcomes at 5 Years
Invasive
96)† Hazard Ratio (95% CI) p Value*
18.1) 1.29 (1.00–1.66) 0.053
16.1) 1.10 (0.83–1.45) 0.52
9.9) 1.13 (0.80–1.60) 0.49
6.8) 0.95 (0.61–1.47) 0.80
11.7) 1.24 (0.90–1.70) 0.20
9.4) 0.92 (0.63–1.35) 0.66
2.4) 2.75 (1.49–5.08) 0.01
plan-Meier estimate; ‡myocardial infarction (MI) definition based ons atRatio
ual O
ective
(n  5
107 (
95 (
59 (
40 (
68 (
54 (
14 (
el; †Ka
on of MI (10).
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Figure 3 Cumulative Risk According to Treatment Strategy of the Composite Outcomes
Shown are Kaplan-Meier curves for the composite of death or recurrent myocardial infarction (MI) (A) and the composite
of death or spontaneous MI (B). Hazard ratios (HRs) and p values were obtained with Cox proportional hazards models. CI  confidence interval.HR 0.95 (95% CI: 0.61−1.47) p=0.80
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March 2, 2010:858–64 5-Year Clinical Outcomes in the ICTUS Trialiew of the lack of a biological rationale for this difference
etween the 2 treatment groups, this finding is likely the
esult of the play of chance.
Consequently, the slightly higher hazard for death or MI
t 5 years associated with the early invasive strategy is
rimarily driven by an early increase in procedure-related
Is and this trend towards higher late noncardiovascular
ortality.
revious NSTE-ACS strategy trials with long-term
ollow-up. The results from our study show important dif-
erences when compared with the 5-year outcomes of the
ITA-3 and FRISC II trials (8,9). In the FRISC II study,
ortality was significantly different at 2-year, but not at 5-year,
ollow-up. In the RITA-3 study, no difference in mortality was
bserved at 2-year, but a difference was shown at 5-year
ollow-up. In the ICTUS trial, there was no difference in
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Figure 5 Cumulative Risk of Death or Spontaneous MI by Treat
(A) Patients divided into 3 risk groups with cutoffs chosen to yield groups with com
as defined in the FRISC II long-term follow-up (9). FRISC score 0 to 1 not shown, Hortality, either at the 2- or 5-year follow up. pWe observed no overall difference in MI between the 2
trategy groups at 5 years, although procedure-related MIs
ere slightly more frequent in the early invasive group.
In the RITA-3 and FRISC II trials, the greatest benefit
f an invasive strategy was seen in high-risk patients.
emarkably, after risk stratification by the FRISC score, we
ound no interaction between treatment strategy and risk
roup. This is unlikely due to a predominance of low-risk
atients being included in the ICTUS trial. Applying the
RISC II definition of risk groups, the percentage of
atients in the intermediate- and high-risk groups in the
CTUS trial (58% and 39%, respectively) are higher com-
ared with those of the FRISC II trial (53% and 30%,
espectively) (9).
The explanation for diverging results between the 3 trials
s likely multifactorial. The trials were done in different time
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5-Year Clinical Outcomes in the ICTUS Trial March 2, 2010:858–64s the use of stents, glycoprotein IIb/IIIa inhibitors, and
ong-term antiplatelet agents and statin treatment. One
ther possible explanation may be the heterogeneity in the
ntensity of revascularization over time. In the ICTUS trial,
he percentage of revascularized patients at 1-year follow-up
as 79% in the early invasive and 54% in the selective
nvasive group, whereas in the RITA-3 and FRISC II trials,
hese percentages were 57% and 28%, and 78% and 44%,
espectively. Therefore, the relatively high intensity of
evascularization in the selective invasive arm in ICTUS
ay be important in explaining the differences in results.
tudy limitations. Procedure-related MIs were analyzed
ainly during initial hospitalization. Therefore, this could
enalize the early invasive arm because other potential MIs
s the result of new revascularizations—likely more com-
on in the selective invasive arm—would have gone unno-
iced. Procedure-related MIs as documented by hospital
ecords were available up to 5-year follow-up, but routine
erial sampling of cardiac biomarkers after PCI in patients
ithout procedure-related complications or clinical symp-
oms was not available. For our current analysis, we included
rocedure-related MIs according to the universal definition
f MI (10). Second, in accordance with the FRISC II and
ITA-3 long-term follow-up, we limited our 5-year
ollow-up to death or MI. We observed no differences in
ehospitalization for anginal complaints and pharmacolog-
cal treatment at 2.7 years (7).
onclusions
n patients presenting with NSTE-ACS and an elevated
roponin T, we could not demonstrate a benefit of an early
nvasive strategy in reducing death or MI at 5 years
ompared with a selective invasive strategy. After risk
tratification by the FRISC score, again no benefit from an
arly invasive strategy was observed. Although many may
refer an early invasive strategy in patients with NSTE-
CS and high-risk features, a selective invasive strategy may
e an attractive alternative in medically stabilized patients.
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